Pharma Stock to look out: Fusion Pharmaceuticals Inc. (FUSN)
Following the earlier article I have shared, I will be on the look out for potential pharmaceuticals stock to trade or invest.
One of the stocks which has a recent upward trend is $Fusion Pharmaceuticals Inc.(FUSN)$
Let me try to explain why I would think we can look out for this stock.
Who is Fusion Pharmaceuticals (FUSN)?
Fusion is a precision-oriented biopharma firm, looking into cancer treatments. Fusion is focused on radiation therapies, using a proprietary development platform and technology to create targeted alpha therapies (TATs), for a safer route in the use of radiopharmaceuticals.
Fusion Pharmaceuticals (FUSN) Technology Competitive Advantage
Fusion’s TAT once connected to their Fast-Clear linker technology in a combination which allows the attachment of alpha particle emitting isotopes directly to antibodies or other targeting molecules.
Once these are introduced into the patient’s body and it will be used to deliver the therapeutic agent directly to the tumor in a highly selective manner, minimizing damage to healthy tissues.
This is an important part of Fusion’s research pipeline, which is the development of this safer route for the use of radiotherapies.
Fusion has already two leading candidates currently in clinical trials.
The first called FPI-2265, is an alpha-emitting radiopharmaceutical undergoing the TATCIST trial in patients suffering from mCRPC, a form of prostate cancer. Data on the first 20 to 30 patients should be available during 1Q24.
The second one which features FPI-1434, the subject of a Phase 1 trial in the treatment of solid tumors expressing IGF-1R. The drug candidate is being tested as both a monotherapy and as a combination therapy with Merck’s KEYTRUDA.
A clinical update of the Phase 1 trial is planned for this coming June 27, at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging.
But there will be a third candidate, FPI-1966, which was part of Fusion’s research program, but it was announced to be discontinued earlier this month.
Why Consider Fusion Pharmaceuticals (FUSN)
I am looking forward to the data catalysis from the 2 leading candidates, FPI 2265 and FPI-1434 over the next 3-9 months.
With the discontinuation of the third candidate, FPI-1966, it is actually a good thing as now Fusion will have the capital and resources to be reallocated to FPI-2265, because FPI-2265 have a better risk-adjusted ROI(Return on Investment).
I would not want to miss out on Fusion future pipeline as I believe the potential in the 2 leading candidates.
Fusion Pharmaceuticals (FUSN) Technical Analysis - Moving Averages
From what I see, FUSN have a pretty good TA on Moving Averages, its current price of $5.10 would make it a good BUY.
Note that it has a 3% upside in After Hours trading on 31 May 23.
Fusion Pharmaceuticals’s (FUSN) 10-Day exponential moving average is 4.30, while Fusion Pharmaceuticals’s (FUSN) share price is $5.1, making it a Buy.
Fusion Pharmaceuticals’s (FUSN) 100-Day exponential moving average is 3.90, while Fusion Pharmaceuticals’s (FUSN) share price is $5.1, making it a Buy.
Fusion Pharmaceuticals’s (FUSN) stock price is $5.1 and Fusion Pharmaceuticals’s (FUSN) 50-day simple moving average is 4.07, creating a Buy signal.
Fusion Pharmaceuticals’s (FUSN) stock price is $5.1 and Fusion Pharmaceuticals’s (FUSN) 100-day simple moving average is 4.01, creating a Buy signal.
Fusion Pharmaceuticals’s (FUSN) stock price is $5.1 and Fusion Pharmaceuticals’s (FUSN) 200-day simple moving average is 3.28, creating a Buy signal.
Fusion Pharmaceuticals (FUSN) Hedge Funds Holding
Hedge funds have increased their holdings by 5.6M shares in the last quarter. They might have share the same sentiment with faith in the two leading candidates from FUSN.
Summary
Even though we are looking forward to FUSN potential of their two candidates, we also need to consider how market and investors are looking at FUSN.
Since their earnings report on 11 May 23, I can see that there is not much activities or strength in its price action.
I will continue to monitor and assess how this stock would be trading over the next 2 weeks before looking at a good entry price for a mid-long term investing.
Appreciate if you could share your thoughts in the comment section whether you are also looking into potential good growth pharmaceuticals stocks.
Do like, share and comment on this article if you find this trading thought useful.
@TigerStars @Daily_Discussion appreciate if you could feature this article so that fellow tiger would benefit from my investing and trading thoughts.
Disclaimer: The analysis and result presented does not recommend or suggest any investing in the said stock. This is purely for Analysis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Nobody is paying attention to this stock why it’s already gone up more than $3.00 since I purchase it
It looks like a very new stock. In this kind of market condition, just be cautious with the new stocks.
I’m only sad I didn’t load up more when it was $2
look like a meme stock…but can keep an eye out.
This company yiu just buy and forget let it sit and don’t sell yet
Let’s just keep this going into the green and let’s make some more money
just what happened to pharmaceutical stocks? they surge
Could targeted radiotherapy be the next focus?
It’s about time to see some upside activities from Fusion!
Suddenly surge keep watching 👀